Cite
Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study
MLA
Mary-Christine Lanoue, et al. “Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases as Compared to Hematological Malignancies: A French Nationwide Study.” European Journal of Internal Medicine, vol. 67, Sept. 2019, pp. 59–64. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cf1b158480810f57f96154c4e27f1d10&authtype=sso&custid=ns315887.
APA
Mary-Christine Lanoue, Annie-Pierre Jonville-Béra, Guillaume Bayer, Marie-Sara Agier, Marion Lepelley, Bertrand Lioger, Marie Zenut, & François Maillot. (2019). Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. European Journal of Internal Medicine, 67, 59–64.
Chicago
Mary-Christine Lanoue, Annie-Pierre Jonville-Béra, Guillaume Bayer, Marie-Sara Agier, Marion Lepelley, Bertrand Lioger, Marie Zenut, and François Maillot. 2019. “Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases as Compared to Hematological Malignancies: A French Nationwide Study.” European Journal of Internal Medicine 67 (September): 59–64. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cf1b158480810f57f96154c4e27f1d10&authtype=sso&custid=ns315887.